Compare Heron Therapeutics Inc (HRTX) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Jones Lang LaSalle Inc — how do they compare? Heron Therapeutics Inc trades at $0.38 (market cap $68.01M), while Jones Lang LaSalle Inc trades at $298.77 (market cap $13.95B). The key difference: Jones Lang LaSalle Inc is far larger — about 205.1× Heron Therapeutics Inc's market cap, and Jones Lang LaSalle Inc is more actively traded (457,462 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Jones Lang LaSalle Inc for 71 Days on average.
| HRTX | JLL | |
|---|---|---|
Market Cap | $68.01M | $13.95B |
Volume | 1,891,941 | 457,462 |
Sector | Health | Real Estate |
52-Week High | $1.49 | $392.79 |
52-Week Low | $0.27 | $280.16 |
Typical Hold Time | 35 Days | 71 Days |
Enterprise Value | $174.75M | $16.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
JLL trades at $298.93, up 0.77% on the day, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue and net income have grown steadily, reaching $26.12B and $792.10M in 2025, respectively, while valuation ratios like a P/E of 14.54 and P/S of 0.53 appear attractive relative to historical norms.
The outlook is positive, supported by analyst consensus favoring a buy rating and a price target of $450.50, implying significant upside. Risks include exposure to real estate market cycles and competitive pressures, but JLL's expanding cash flow and strategic acquisitions in high-growth areas like data centers provide a solid foundation for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
